Table 1.
Characteristics of 39 OCAC studies and 39,398 participants of European ancestry included in the Mendelian randomisation analysis
| Study acronyma | Country | Diagnosis (years) | Median (range) age at diagnosis/interview | Invasive cases (N) | Borderline cases (N) | All cases (N)b | Controls (N) | Mean (SD) height (cm)c |
|---|---|---|---|---|---|---|---|---|
| AUS | Australia | 2002–2006 | 58 (19–80) | 859 | 1 | 860 | 977 | 163 (6.9) |
| BAV | Germany | 2002–2008 | 58 (24–83) | 96 | 5 | 102 | 143 | 164 (5.8) |
| BEL | Belgium | 2007–2010 | 46 (19–87) | 275 | 0 | 275 | 1347 | — |
| DOV | USA | 2002–2009 | 57 (35–74) | 904 | 327 | 1231 | 1487 | 166 (6.5) |
| GER | Germany | 1993–1998 | 57 (21–75) | 189 | 24 | 213 | 413 | 163 (6.0) |
| GRR | USA | 1981–2012 | 48 (21–83) | 125 | 0 | 125 | 0 | — |
| HAW | USA | 1993–2008 | 56 (27–87) | 60 | 20 | 80 | 157 | 163 (6.6) |
| HJO | Germany | 2007–2011 | 54 (18–88) | 261 | 13 | 290 | 273 | — |
| HMO | Belarus | 2006–2011 | 45 (22–76) | 142 | 0 | 143 | 138 | — |
| HOC | Finland | 1975–1999 | 46 (18–86) | 210 | 8 | 239 | 447 | — |
| HOP | USA | 2003–2009 | 58 (25–94) | 567 | 71 | 723 | 1464 | 163 (6.8) |
| HSK | Germany | 2000–2007 | 58 (18–81) | 147 | 9 | 156 | 0 | 165 (5.6) |
| LAX | USA | 1989–2008 | 58 (31–88) | 278 | 0 | 278 | 0 | — |
| MAL | Denmark | 1994–1999 | 57 (31–80) | 440 | 138 | 578 | 828 | 166 (6.1) |
| MAY | USA | 2000–2010 | 61 (20–93) | 699 | 79 | 778 | 743 | 165 (6.3) |
| MCC | Australia | 1990–2008 | 65 (45–79) | 66 | 0 | 66 | 66 | 159 (7.0) |
| MDA | USA | 1997–2009 | 62 (23–88) | 375 | 0 | 375 | 384 | — |
| MSK | USA | 1997–2010 | 57 (18–89) | 450 | 0 | 450 | 593 | — |
| NCO | USA | 1999–2008 | 57 (20–75) | 722 | 171 | 896 | 792 | 163 (6.4) |
| NEC | USA | 1992–2003 | 52 (21–78) | 654 | 232 | 904 | 1009 | 163 (6.7) |
| NJO | USA | 2002–2009 | 60 (25–88) | 169 | 0 | 169 | 181 | 163 (6.9) |
| NOR | Norway | 2001–2010 | 51 (18–86) | 236 | 12 | 248 | 371 | — |
| NTH | Netherlands | 1997–2008 | 55 (18–83) | 292 | 3 | 295 | 323 | 167 (6.0) |
| ORE | USA | 2007–2011 | 58 (22–86) | 55 | 9 | 65 | 0 | — |
| OVA | Canada | 2002–2009 | 58 (19–80) | 640 | 161 | 801 | 748 | — |
| POC | Poland | 1998–2008 | 55 (23–82) | 423 | 0 | 423 | 417 | — |
| POL | Poland | 2000–2004 | 56 (24–74) | 236 | 0 | 236 | 223 | 162 (5.6) |
| PVD | Denmark | 2004–2009 | 63 (30–88) | 168 | 0 | 168 | 0 | 165 (6.5) |
| RMH | UK | 1993–1996 | 52 (26–73) | 148 | 7 | 155 | 0 | — |
| SEA | UK | 1998–2011 | 57 (19–78) | 1447 | 76 | 1530 | 6004 | 162 (6.3) |
| SOC | UK | 1993–1998 | 62 (22–92) | 268 | 20 | 288 | 0 | — |
| SRO | UK | 1999–2001 | 59 (34–84) | 158 | 0 | 158 | 0 | — |
| STA | USA | 1997–2002 | 50 (20–64) | 251 | 10 | 261 | 313 | 165 (6.7) |
| TOR | Canada | 1995–2007 | 58 (26–85) | 603 | 0 | 605 | 440 | 163 (7.1) |
| UCI | USA | 1993–2005 | 56 (18–86) | 277 | 141 | 418 | 367 | 165 (6.6) |
| UKO | UK | 2006–2010 | 63 (19–89) | 718 | 0 | 718 | 1104 | 162 (6.7) |
| UKR | UK | 1991–2009 | 54 (24–77) | 47 | 0 | 47 | 0 | — |
| USC | USA | 1992–2010 | 57 (22–82) | 693 | 152 | 845 | 1047 | 165 (6.8) |
| WOC | Poland | 1997–2010 | 44 (20–81) | 201 | 2 | 203 | 204 | — |
All participants were of >90% European ancestry according to genetic markers of ancestry.
aOCAC is an international collaboration of largely case–control studies. See Supplementary Table 1 for study names and references. To maximise power, nine case-only studies were grouped for analysis with case–control studies from the same region: HSK combined with GER; GRR with HOP; PVD with MAL; RMH, SOC, SRO, UKR with SEA and UKO (‘UK group’); ORE with DOV; LAX with UCI.
bCases had primary ovarian (n = 15,636), fallopian tube (n = 180) or peritoneal (n = 552) cancer or ovarian/tubal/peritoneal tumours of undetermined site (n = 27).
cUsual adult height. Height is summarised for 22 studies (20 case–control studies) where >50% participants had data available (AUS, BAV, DOV, GER, HAW, HOP, HSK, MAL, MAY, MCC, NCO, NEC, NJO, NTH, POL, PVD, SEA, STA, TOR, UCI, UKO, USC). Sixteen of these 22 studies were also used in conventional height analyses, as they provided data on potential confounders (age, parity, use of oral contraceptives, education, and age at menarche) for >50% of participants (AUS, DOV, GER, HAW, HOP, MAL, NCO, NEC, NJO, NTH, POL, STA, TOR, UCI, UKO, USC).
OCAC Ovarian Cancer Association Consortium, SD standard deviation